eFFECTOR Therapeutics (EFTR) Peer Comparison
$0.00
$0.00 (0.00%)As on 27-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 17,326 | 16,614 | 13,400 | 12,305 |
Revenue ($ Mln) |
0 | 2,782 | 1,054 | 2,436 | 670 |
Net Profit ($ Mln) |
-34.63 | 491.50 | 755.85 | 860.62 | -319.95 |
Net Margin (%) |
-21,376.54 | 17.67 | 71.69 | 35.33 | -47.79 |
RoE (%) |
-- | 110.09 | -- | 42.98 | -71.14 |
Price to Earnings |
-- | 36.49 | 19.38 | 17.01 | -- |
Price-To-Book |
0.00 | 39.43 | 10.05 | 7.27 | 26.44 |
Income Statement ($ Mln)
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.16 | 1,885.84 | 266.72 | 1,830.21 | 240.74 |
|
Cost of Revenue
|
0.11 | 1,361.34 | 44.40 | 72.55 | 12.49 |
|
Gross Profit
|
-0.11 | 524.51 | 222.32 | 1,757.66 | 228.24 |
|
Operating Expenses
|
32.67 | 187.68 | 677.86 | 1,586.78 | 433.24 |
|
Operating Profit (EBIT)
|
-33.15 | 336.83 | -455.54 | 170.89 | -205.00 |
|
Other Income
|
0.00 | 7.07 | -- | -0.20 | 0.77 |
|
Profit before Tax
|
-34.63 | 335.68 | -474.14 | 257.52 | -206.49 |
|
Provision for Tax
|
-0.02 | 52.87 | 7.30 | 49.76 | 2.78 |
|
Profit after Tax (Net Income)
|
-34.63 | 282.81 | -481.45 | 207.77 | -205.28 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Consolidated Profit
|
-8.36 | 245.37 | -583.19 | 182.28 | -205.28 |
Liabilities ($ Mln)
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.83 | 558.95 | -145.70 | 2,263.91 | 271.34 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Non-Current Liabilities
|
0.74 | 172.75 | 234.78 | 284.17 | 372.93 |
|
Current Liabilities
|
25.57 | 925.13 | 736.51 | 394.28 | 105.46 |
|
Total Liabilities
|
20.54 | 1,656.83 | 825.59 | 2,942.36 | 765.55 |
Assets ($ Mln)
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.88 | 1,063.00 | 122.87 | 1,624.40 | 346.03 |
|
Current Assets
|
26.25 | 593.83 | 702.72 | 1,317.96 | 419.52 |
|
Total Assets
|
20.54 | 1,656.83 | 825.59 | 2,942.36 | 765.55 |
|
Total Debt*
|
20.25 | 142.12 | 743.06 | 189.94 | 383.50 |
|
Net Current Assets
|
0.68 | -331.30 | 505.38 | 923.68 | 110.03 |
Cashflow ($ Mln)
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-29.55 | 433.37 | -467.36 | 333.32 | -153.89 |
|
Cash Flow from Investing Activities
|
14.48 | -34.63 | 286.47 | -26.96 | -96.16 |
|
Cash from Financing Activities
|
21.23 | -182.64 | 134.29 | -546.05 | 253.05 |
|
Net Cash Inflow / Outflow
|
-- | -426.47 | -- | -161.21 | -76.36 |
Ratios
Profitability Ratios
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-183.99 | 44.32 | -65.14 | 8.10 | -36.17 |
|
ROE (%)
|
3,771.56 | 59.83 | -818.43 | 8.74 | -61.29 |
|
ROA (%)
|
-68.38 | 18.80 | -50.27 | 6.91 | -28.17 |
|
EBIT Margin (%)
|
-19,724.69 | -- | -- | -- | -- |
|
Net Margin (%)
|
-21,376.54 | 15.00 | -180.51 | 11.35 | -85.27 |
|
Cash Profit Margin (%)
|
-0.19 | -- | -- | -- | -- |
Growth Ratios
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-95.44 | 0.29 | 4.21 | 0.14 | -0.01 |
|
EBIT Growth (%)
|
4.00 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
3.13 | 15.26 | 17.45 | 13.98 | -16.31 |
|
EPS Growth (%)
|
32.86 | 0.17 | 0.18 | 0.18 | -0.15 |
|
Book Value Growth (%)
|
110.81 | -- | -- | -- | -- |
Valuation Ratios
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.03 | 34.49 | -14.81 | 36.14 | -14.05 |
|
Price / Book Value
|
-0.22 | 17.45 | -48.94 | 3.32 | 10.63 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.10 | 26.63 | -18.18 | 23.67 | -16.30 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.25 | -5.10 | 0.08 | 1.41 |
|
Short term debt to equity ratio
|
24.27 | 0.52 | -2.99 | 0.01 | 0.04 |
|
Current Ratio
|
1.03 | 0.64 | 0.95 | 3.34 | 3.98 |
|
Quick Ratio
|
1.03 | 0.64 | 0.67 | 3.30 | 3.07 |
|
Interest Coverage
|
-10.62 | 688.87 | -9.76 | 3.75 | -10.27 |
Operating Efficiency Ratios
| eFFECTOR Therapeutics (EFTR) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
10.49 | 15.82 | 13.45 | 12.97 | 0.00 |
|
Asset Turnover
|
0.00 | 1.25 | 0.28 | 0.61 | 0.33 |
|
Receivable days
|
-- | 53.44 | 32.72 | 45.12 | 1.07 |
|
Inventory Days
|
-88.84 | 0.00 | 1,397.01 | 127.43 | -631.91 |
|
Payable days
|
6,278.35 | 8.71 | 804.62 | 167.24 | 566.22 |
|
Cash Conversion Cycle
|
-- | 44.73 | 625.11 | 5.31 | -1,197.07 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
